培美曲塞与多西他赛联合顺铂治疗晚期肺腺癌的临床比较观察  

Study of Pemetrexed plus Cisplatin Regimen Versus Docetaxel plus Platinum Regimen in the Treatment of Advanced Lung Adenocarcinoma

作　　者：秦亚光[1] 程传耀[1] 王亚秋[1] 卢红[1] 

机构地区：[1]河南大学淮河医院肿瘤科,河南开封475000

出　　处：《肿瘤基础与临床》2016年第1期32-35,共4页journal of basic and clinical oncology

摘　　要：目的比较观察培美曲塞与多西他赛联合顺铂治疗晚期肺腺癌的疗效和毒副反应。方法 76例晚期肺腺癌患者中,应用培美曲塞联合顺铂治疗45例(培美曲塞组),多西他赛联合顺铂治疗31例(多西他赛组),比较2组疗效和毒副反应。结果 76例患者均可评价疗效和毒副反应,培美曲塞组和多西他赛组有效率分别为46.7%、41.9%,疾病控制率分别为75.6%、71.0%,差异均无统计学意义(P均>0.05);培美曲塞组和多西他赛组中位无进展生存期分别为6.4、5.3个月。中位总生存期分别为12.0、10.3个月,差异均无统计学意义(P均>0.05);培美曲塞组白细胞减少、血小板减少、贫血、恶心呕吐的发生率均低于多西他赛组,差异均有统计学意义(P均>0.05)。结论培美曲塞与多西他赛联合顺铂治疗晚期肺腺癌患者的疗效相似,但培美曲塞的毒副反应更重。Objective To compare the efficacy and toxicities of patients with advanced lung adenocarcinoma treated by pemetrexed plus cisplatin regimen or docetaxel plus platinum regimen. Methods Of the 76 patients with advanced lung adenocarcinoma,45 patients received the pemetrexed plus cisplatin regimen（ the pemetrexed group）,and the other 31 patients received the docetaxel plus platinum regimen（ the docetaxel group）. The efficacy and toxicities of the two groups were compared. Results The efficacy and toxicities of all the patients could be evaluated.No statistical significance were found between the pemetrexed group and the docetaxel group in the response rate（ 46. 7% vs 41. 9%）,the disease control rate（ 75. 6% vs 71. 0%）,the median progress free survival（ 6. 4 vs 5. 3months）,the median overall survival（ 12. 0 vs 10. 3 months）（ P 〈0. 05）. The incidences of leukopenia,thrombocytopenia,anemia,nausea and vomiting in the pemetrexed group were lower those in the docetaxel group（ P 〈0. 05）.Conclusion Pemetrexed plus cisplatin regimen has the similar efficacy and less toxicities compared with docetaxel plus cisplatin regimen in the treatment of advanced lung adenocarcinoma.

关 键 词：晚期肺腺癌 化疗 培美曲塞 多西他赛 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]